Ridgeline Discovery
Cecile Gstalder is a Senior Scientist at Ridgeline Discovery since October 2022, with previous experience as a Scientist II at FogPharma from July 2021 to August 2022 and as a Postdoctoral Research Fellow at Dana-Farber Cancer Institute from February 2016 to October 2020, where tumor-intrinsic mechanisms of resistance to checkpoint blockade were characterized to inform combination therapies in immunotherapy. Prior to that, Cecile Gstalder completed a PhD at CNRS from October 2011 to September 2015, focusing on sphingolipid metabolism and its implications for renal cell carcinoma. Cecile Gstalder holds a PharmD and multiple degrees in cancer research and biotechnology from Université Paul Sabatier Toulouse III and the University of Strasbourg.
This person is not in any offices
Ridgeline Discovery
Ridgeline Discovery, a Versant Ventures Discovery Engine, creates and operates Versant-financed innovative biotech companies in partnership with entrepreneurs, industry and leading academics across Europe. In recent years, Ridgeline has assembled an international team of >50 highly experienced drug discovery professionals and built and operated several new successful companies, including Black Diamond Therapeutics (NASDAQ: BDTX), Bright Peak Therapeutics and Monte Rosa Therapeutics (NASDAQ: GLUE). Ridgeline is currently expanding its capabilities in Basel to support further company creation efforts in small molecules, biologics, and gene/cell therapy with focus on oncology and immunology.